0QF Stock Overview
A biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Moderna, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$38.68 |
| 52 Week High | US$155.30 |
| 52 Week Low | US$34.50 |
| Beta | 1.59 |
| 1 Month Change | -4.90% |
| 3 Month Change | -36.99% |
| 1 Year Change | -55.32% |
| 3 Year Change | -82.29% |
| 5 Year Change | 119.45% |
| Change since IPO | 126.60% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0QF | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -5.1% | -2.9% | -2.6% |
| 1Y | -55.3% | -14.7% | 6.9% |
Return vs Industry: 0QF underperformed the German Biotechs industry which returned -14.7% over the past year.
Return vs Market: 0QF underperformed the German Market which returned 6.9% over the past year.
Price Volatility
| 0QF volatility | |
|---|---|
| 0QF Average Weekly Movement | 9.9% |
| Biotechs Industry Average Movement | 6.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 0QF's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 0QF's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 5,600 | Stephane Bancel | www.modernatx.com |
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics.
Moderna, Inc. Fundamentals Summary
| 0QF fundamental statistics | |
|---|---|
| Market cap | €14.53b |
| Earnings (TTM) | -€2.13b |
| Revenue (TTM) | €4.87b |
3.0x
P/S Ratio-6.8x
P/E RatioIs 0QF overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0QF income statement (TTM) | |
|---|---|
| Revenue | US$5.08b |
| Cost of Revenue | US$6.48b |
| Gross Profit | -US$1.40b |
| Other Expenses | US$824.00m |
| Earnings | -US$2.22b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.78 |
| Gross Margin | -27.55% |
| Net Profit Margin | -43.77% |
| Debt/Equity Ratio | 0% |
How did 0QF perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 09:34 |
| End of Day Share Price | 2024/12/18 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Moderna, Inc. is covered by 42 analysts. 24 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Argus Research Company |
| Ishan Majumdar | Baptista Research |
| Huidong Wang | Barclays |